Latest Adalimumab Stories

Safety results were similar between groups Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24. The ADACTA trial, conducted in 325 patients with RA showed that tocilizumab was more effective than adalimumab for DAS28 remission (39.9%...

Further data reveals there is no consistent criteria for biologic reimbursement in place Data from a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates the vast inequalities in access to biologics for the treatments of rheumatoid arthritis (RA) across 46 European countries, with 22% (n=10) of countries having no biologic reimbursed at all. In the 36 countries with reimbursed biologics, only 27 had more than five biologics...

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA® (adalimumab) in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS). At week 12, nearly twice as many HUMIRA patients compared to those receiving placebo achieved the primary endpoint, defined as at least a 40 percent improvement in the peripheral SpA...

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). These 10-year HUMIRA studies, DE019 and DE020, are among the longest, open-label trials in RA. Results presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany, include...

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA® (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Results were presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany. ABILITY-1 is the first...

Education is key to success; functional disability negatively impacts job performance As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood. Arthritis is...

"Ankylosing spondylitis is now being treated with regenerative medicine at he center for regenerative medicine." according to A.J. Farshchian MD an orthopedic regenerative practitioner at the center for regenerative medicine. Miami, Florida (PRWEB) May 30, 2012 "Ankylosing spondylitis is now being treated with regenerative medicine at he center for regenerative medicine." according to A.J. Farshchian MD an orthopedic regenerative practitioner at the center for regenerative...

LA JOLLA, Calif., May 31, 2012 /PRNewswire/ -- Scripps Research Institute Professor Richard A. Lerner, MD, has won a prestigious international honor, the Prince of Asturias Award for Scientific and Technical Research, according to an announcement made today by the Prince of Asturias Foundation. Lerner shares the award with British biochemist Sir Gregory Winter, PhD. Sometimes called the "Spanish Nobel Prize," the Prince of Asturias Award for Scientific and Technical Research is...

ABBOTT PARK, Ill., May 29, 2012 /PRNewswire/ -- Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA® (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012. The presentations include two of the longest open-label extension studies in rheumatoid arthritis (RA), featuring long-term data for disease activity and radiographic inhibition. Data will also be presented...

PARIS, May 14, 2012 /PRNewswire/ -- - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] (NYSE: BMY) today announced that the company will present 18 abstracts on abatacept at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in...